![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves Firdapse for Treatment of LEMS
FDA Approves Firdapse for Treatment of LEMS
![Red_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Red_Approved_Stamp.gif?t=1578447203&width=430)
December 10, 2018
The FDA gave the go-ahead for Catalyst Pharmaceuticals’ Firdapse (amifampridine) for the treatment of adults with Lambert-Eaton Myasthenic Syndrome (LEMS).
LEMS is a rare autoimmune disease that causes proximal muscle weakness and fatigue in patients, with life-threatening symptoms possible when a patient’s respiratory muscles are weakened. It is estimated to affect 1 in 100,000 individuals in the U.S.
The FDA’s approval was based on positive results for two Phase 3 studies in which patients treated with the drug saw rapid, steady and significant improvements in muscle function, as well as a reduction in fatigue and weakness.
Upcoming Events
-
21Oct